Supplementary data: Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

dataset

posted on 2024-06-28, 13:35 authored by Jose Nativi-Nicolau, Ali YilmazAli Yilmaz, Noel Dasgupta, Richard Macey, James Cochrane, Judith Peatman, Catherine Summers, Jennifer Luthman, Ronald Zolty

These are peer-reviewed supplementary materials for the article 'Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review' published in the Journal of Comparative Effectiveness Research.

Table S1: Embase search strategy: combining 6MWT, mortality, hospitalization, and HF.
Table S2: Medline search strategy: combining 6MWT, mortality, hospitalization, and HF.
Table S3: Gray literature – Conferences searched.
Table S4: JBI Risk of bias assessment — randomized controlled trials
Table S5: JBI Risk of bias assessment — cross sectional
Table S6: JBI Risk of bias assessment — cohort
Table S7: Study and population characteristics
Table S8: 6MWT and hospitalization: separate outcomes
Table S9: 6MWT and mortality: separate outcomes

Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.